Introduction
============

The combination of efavirenz (EFV), tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or lamivudine (3TC) was established as preferred first-line antiretroviral therapy (ART) for HIV in 2013 WHO guidelines \[[@R1]\]. However, first-line EFV is no longer the preferred choice in most patients \[[@R2]\] because of the availability of new combinations with greater efficacy and fewer side effects and emergence of high levels of transmitted resistance to nonnucleoside/nucleotide reverse transcriptase inhibitors in some low/middle income countries (LMICs) \[[@R3]\]. Despite reductions in newly diagnosed people living with HIV (PLWHIV) starting EFV + TDF + FTC/3TC, large numbers remain on this regimen \[[@R4]\] and so there is a need to evaluate its long-term effectiveness.

An analysis from the UK Collaborative HIV Cohort (UK CHIC) Study showed that PLWHIV on ART regimens with initial viral suppression have annual rates of virological rebound (200 copies/ml threshold) that decrease from around 9/100 person-years in the first year to less than 3/100 person-years after some years on treatment \[[@R5]\]; the authors projected that some PLWHIV would maintain suppression for decades without treatment change. However, few studies have evaluated long-term viral suppression using a single combination.

We estimated rates of virological failure, treatment interruption and treatment switches for PLWHIV with initial viral suppression on first-line EFV + TDF + FTC/3TC within a multinational collaboration of European HIV cohort studies. We evaluated demographic and clinical risk factors for these events.

Methods
=======

We analysed data, merged in June 2015, from 20 cohorts in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) \[[@R6]\]. Additional data were added from the UK CHIC September 2016 dataset, to align last recorded follow-up with other cohorts.

PLWHIV were included if they were ART-naïve at cohort enrolment and started first-line EFV + TDF + FTC/3TC at age at least 16 years with viral suppression (defined as one measurement undetectable or \<200 copies/ml) within 9 months. Initial regimen was ignored if it changed within 1 week of first treatment. PLWHIV were excluded if their last viral load measurement was less than 9 months after starting ART, if treatment was interrupted before viral suppression or if at least one pre-ART viral load measurement was either undetectable or ≤50 copies/ml within 1 year prior to starting ART (to remove those who may have started ART before the date recorded). COHERE cohorts with fewer than 20 PLWHIV meeting the inclusion criteria were dropped.

Statistical analysis
--------------------

Follow-up started at the date of viral suppression. Virological failure was defined as one measurement ≥ 200 copies/ml to allow consistency of analysis across cohorts and over the timespan considered. Treatment interruption was defined as cessation of all ART, but interruptions of up to 1 week were ignored. We also estimated rates of virological failure whilst on EFV + TDF + FTC/3TC, of complete interruption of ART directly from treatment with EFV + TDF + FTC/3TC and of switching from EFV + TDF + FTC/3TC to any other regimen.

Piecewise exponential time-to-event models were used to estimate event rates, which were estimated for yearly intervals from initial viral suppression, with a single rate estimated for follow-up more than 9 years. Rates were first estimated without adjustment for patient characteristics. For virological failure and treatment interruption, cause-specific piecewise exponential models were fitted with censoring for the other event (i.e. only the first virological failure *or* interruption event was counted): these were used to estimate the rates and cumulative incidence of each event, accounting for the competing risk of the other \[[@R7]\].

We estimated adjusted associations of the virological failure and treatment interruption outcomes with patient sex, mode of acquisition (MSM \[reference\], female heterosexual, male heterosexual, female IDU, male IDU), ethnicity (white \[reference\], Black, Asian, other), prior AIDS diagnosis, baseline CD4^+^ cell count (0--200 \[reference\], 200--350, 350--500, \>500 cells/μl) and viral load (0--20k, 20k--100k \[reference\], 100k--500k, \>500k copies/ml), time-updated age (\<25, 25--35, 35--45 \[reference\], 45--55, \>55 years), year of starting ART (2002--2004, 2005--2006, 2007--2008, 2009--2010 \[reference\], 2011--2012, 2013--2014) and cohort. For five cohorts, ethnicity was not recorded so this variable was set to reference (i.e. 'white') for the purpose of multivariable analysis. For categorical variables, the group with highest frequency was chosen as reference. Baseline CD4^+^ cell counts and viral load were defined as the last measurement obtained within the 6-month period before ART start. Follow-up was censored at 6 months after last recorded viral load or at death. The adjusted analyses were conducted without censoring at switch to other ART regimen.

For analyses adjusted for patient characteristics, full covariate data were available in 83.0% of cases (ignoring ethnicity for cohorts without this information recorded). Multiple imputation using chained equations was implemented using the Stata 'ice' package \[[@R8]\], with 17 imputed datasets for each event \[[@R9]\]. Imputation models included log event times and indicators for cohorts and events. Predictive mean matching was employed for baseline CD4^+^, viral load and age. Imputation models used square root CD4^+^ cell counts and log~10~ viral load. MSM status, sex and IDU status were imputed separately; these factors were then combined for analysis models with IDU status considered the primary mode of acquisition in PLWHIV who were also MSM. PLWHIV with transfusion-related or 'other' acquisition were excluded due to low numbers.

Results
=======

The study population included 19 527 PLWHIV (Fig. S1). The majority mode of acquisition was MSM (59.6%). Where known, white ethnicity was most common (70.2%) with 20.6% Black and 4.2% Asian ethnicities (further details in Tables S1 and S2).

Unadjusted incidence rates of virological failure and ART interruption according to years since initial viral suppression are shown in Fig. [1](#F1){ref-type="fig"}a and b. For these analyses (counting only the first event), there were 2655 (13.6%) virological failure events and 1521 (7.8%) treatment interruption events, and median (interquartile range) follow-up was 3.7 (2.0--5.6) years. For analyses restricted to those remaining on EFV + TDF + FTC/3TC, incidence rates are shown in Fig. [1](#F1){ref-type="fig"}c and d: there were 1879 (9.6%) virological failure outcomes and 1062 (5.4%) treatment interruption outcomes. Results in supplementary material show rates of switching from EFV + TDF + FTC/3TC to any other ART regimen, the combined incidence of 'virological failure or treatment interruption' (Fig. S2), and cumulative incidence functions for virological failure and ART interruption (Fig. S3).
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Fifty-five PLWHIV with transfusion-acquired HIV and 262 with 'other' acquisition were excluded from multivariable analyses. Adjusted associations of patient characteristics with virological failure and treatment interruption are shown in Table [1](#T1){ref-type="table"}. MSM had lowest rates of virological failure and treatment interruption while IDU had markedly higher rates of treatment interruption. Black ethnicity was associated with higher rates of virological failure and treatment interruption. A prior AIDS diagnosis was associated with higher rates of virological failure but lower rates of treatment interruption. Baseline CD4^+^ cell count more than 200 cells/μl was associated with lower rate of virological failure, but those with baseline CD4^+^ above 500 cells/μl had higher rates of treatment interruption. Rates of virological failure increased with increasing baseline viral load, but there was little evidence that baseline viral load was associated with treatment interruption. Rates of both virological failure and treatment interruption declined in later compared with earlier calendar years of starting ART. Age below 35 years was associated with a higher rate of virological failure and of treatment interruption.

Discussion
==========

Amongst PLWHIV enrolled in a large collaboration of European cohort studies starting first-line EFV + TDF + FTC/3TC, rates of virological failure and treatment interruption declined over 3 years following initial virological suppression before stabilizing at low levels: the subsequent combined incidence rate of virological failure or treatment interruption was below 4/100 person-years for PLWHIV remaining on ART, and was below 3.5/100 person-years considering only those on the EFV + TDF + FTC/3TC regimen.

The regimen included in this analysis, EFV + TDF + FTC/3TC, is no longer preferred first-line ART in most patients: WHO now recommends dolutegravir-based ART \[[@R2]\] following evidence that this has improved efficacy and reduced side effects \[[@R10]\]. Tenofovir alafenamide may also have a better side effect profile than TDF in some combinations \[[@R11]\]. However, whilst agreements are in place to provide dolutegravir-based ART at low cost in LMICs \[[@R4]\], EFV + TDF + FTC/3TC is available as a low-cost generic option worldwide and there is not strong evidence for an individual-level benefit of switching off this regimen in virologically suppressed patients \[[@R4]\]. At present, there are also concerns regarding the use of dolutegravir in women who may become pregnant \[[@R12]\].

We found lower rates of both virological failure and treatment interruption for PLWHIV on first-line EFV + TDF + FTC/3TC in comparison to UK patients starting any 3 + drug ART \[[@R5]\], for whom a combined incidence of around 12.5/100 person-years was reported in the first year from baseline (*c.* 9.0/100 person-years) dropping to less than 6/100 person-years beyond 3 years (*c.* \<4/100 person-years). Long-term studies have not yet been published regarding the durability of viral suppression on first-line dolutegravir-based ART, but as there is evidence from trials of superior viral suppression on dolutegravir vs. EFV at 48, 96 and 144 weeks \[[@R13]\] it is likely that our results reflect an upper limit on the virological failure rates that would be expected for equivalent patients on dolutegravir-based ART.

Black ethnicity was associated with virological failure and treatment interruption, which is consistent with the findings of O'Connor *et al.*\[[@R5]\] for the United Kingdom. Non-MSM groups were also at higher risk of these events, with particularly strong associations for IDUs as found previously \[[@R14]\]. Rates of virological failure among non-white and non-MSM individuals may vary between countries and healthcare settings, but these findings reinforce the need to identify subpopulations with worse outcomes on ART \[[@R15]\] and understand the underlying causes. Both ethnicity and mode of acquisition are associated with social and economic factors which themselves may vary between cohorts. Age less than 35 was associated with higher rates of virological failure and treatment interruption, consistent with previous findings in both high income \[[@R5],[@R14]\] and LMIC \[[@R16]\] settings. Differences in rates of virological failure between demographic groups are likely to be driven by adherence \[[@R17]\].

Consistent with previous literature \[[@R5],[@R18]\] viral load before starting treatment was associated with rates of virological failure on treatment, whilst baseline CD4^+^ cell count more than 200 cells/μl was associated with a lower rate of virological failure on treatment \[[@R19]\]. PLWHIV with the highest baseline CD4^+^ cell counts (\>500 cells/μl) had highest rate of treatment interruption, consistent with previous studies \[[@R19],[@R20]\], which could reflect differences in behaviour and clinical counselling for PLWHIV at lower immediate risk of HIV-related morbidity. Most data in this analysis were from the period before European guidelines recommended starting ART in all PLWHIV irrespective of CD4^+^ cell count.

Rates of virological failure and treatment interruption for PLWHIV declined in later compared with earlier calendar years of ART initiation. This may be linked to a reduction in pill count as combination tablets became available \[[@R21]\], but a limitation of our analysis is that we do not have detailed information on combination dosing (e.g. number of pills/day). Another limitation is that we cannot determine whether treatment switching from first-line regimen was driven by side effects.

We have quantified long-term virological suppression achieved using first-line EFV + TDF + FTC/3TC across a large multinational cohort collaboration. This regimen remains in use worldwide, so the low failure rate with sustained virological suppression for up to a decade on treatment is encouraging. The substantial differences in rates of virological failure and treatment interruption according to demographic and clinical characteristics may be useful for targeted monitoring and adherence interventions.
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Adjusted (for other characteristics in the table) associations (incidence rate ratios) of patient characteristics with virological failure and treatment interruption.

                                                                                                                VF on ART (censor at interruption, LTFU, death)   Treatment interruption (censor at VF, LTFU, death)                                        
  ---------------------------------------------------------------------------------- ----------------- -------- ------------------------------------------------- ---------------------------------------------------- --------- ------ ------------------- ---------
  ART regimen                                                                        On FTC            17 945   2256                                              1 \[Reference\]                                      0.140     1322   1 \[Reference\]     0.710
                                                                                     On 3TC            1265     340                                               1.13 (0.96, 1.34)                                              165    1.05 (0.83, 1.32)   
  Mode of acquisition[^b^](#TF1-2){ref-type="table-fn"}                              MSM               12 399   1467                                              1 \[Reference\]                                      \<0.001   825    1 \[Reference\]     \<0.001
                                                                                     Hetero (female)   2750     453                                               1.19 (1.05, 1.35)                                              271    1.17 (0.99, 1.39)   
                                                                                     Hetero (male)     3486     577                                               1.32 (1.18, 1.47)                                              303    1.26 (1.08, 1.47)   
                                                                                     IDU (female)      123      17                                                1.15 (0.70, 1.89)                                              20     3.18 (2.00, 5.04)   
                                                                                     IDU (male)        451      82                                                1.53 (1.21, 1.94)                                              68     3.13 (2.40, 4.08)   
  Ethnicity[^b^](#TF1-2){ref-type="table-fn"}^,^[^c^](#TF1-3){ref-type="table-fn"}   White             8226     1015                                              1 \[Reference\]                                      \<0.001   627    1 \[Reference\]     \<0.001
                                                                                     Asian             484      63                                                1.12 (0.86, 1.45)                                              32     0.85 (0.59, 1.23)   
                                                                                     Black             2363     435                                               1.33 (1.16, 1.53)                                              331    1.54 (1.29, 1.82)   
                                                                                     Other             575      56                                                0.83 (0.63, 1.09)                                              55     1.03 (0.78, 1.37)   
  Prior AIDS Dx                                                                      No                16 803   2124                                              1 \[Reference\]                                      0.001     1298   1 \[Reference\]     0.059
                                                                                     Yes               2407     472                                               1.20 (1.08, 1.34)                                              189    0.85 (0.72, 1.01)   
  Baseline CD4^+^ cell count (cells/μl)[^b^](#TF1-2){ref-type="table-fn"}            0--200            8879     1417                                              1 \[Reference\]                                      0.005     673    1 \[Reference\]     \<0.001
                                                                                     200--350          6432     838                                               0.90 (0.82, 0.99)                                              514    0.97 (0.85, 1.10)   
                                                                                     350--500          2707     238                                               0.77 (0.67, 0.90)                                              199    1.17 (0.98, 1.39)   
                                                                                     Over 500          1191     103                                               0.89 (0.72, 1.11)                                              101    1.60 (1.28, 2.01)   
  Baseline VL (copies/ml)[^b^](#TF1-2){ref-type="table-fn"}                          0--20k            4580     416                                               0.72 (0.64, 0.82)                                    \<0.001   362    0.88 (0.76, 1.01)   0.262
                                                                                     20k--100k         6696     824                                               1 \[Reference\]                                                534    1 \[Reference\]     
                                                                                     100k--500k        6130     997                                               1.28 (1.16, 1.42)                                              456    0.98 (0.86, 1.12)   
                                                                                     Over 500k         1805     358                                               1.53 (1.34, 1.74)                                              135    1.03 (0.85, 1.26)   
  Start of ART                                                                       2002--2004        847      259                                               1.64 (1.35, 2.01)                                    \<0.001   137    1.52 (1.16, 2.00)   0.009
                                                                                     2005--2006        2000     460                                               1.34 (1.18, 1.53)                                              226    1.15 (0.96, 1.37)   
                                                                                     2007--2008        4137     683                                               1.14 (1.03, 1.27)                                              387    1.10 (0.96, 1.27)   
                                                                                     2009--2010        6058     732                                               1 \[Reference\]                                                443    1 \[Reference\]     
                                                                                     2011--2012        4763     381                                               0.85 (0.75, 0.97)                                              247    0.94 (0.80, 1.11)   
                                                                                     2013--2014        1405     81                                                0.86 (0.68, 1.09)                                              47     0.78 (0.57, 1.07)   
  Time-updated age (years)[^d^](#TF1-4){ref-type="table-fn"}                         Under 25          912      118                                               1.10 (0.87, 1.38)                                    0.007     102    1.90 (1.48, 2.44)   \<0.001
                                                                                     25--35            5613     765                                               1.16 (1.05, 1.28)                                              478    1.19 (1.04, 1.35)   
                                                                                     35--45            7127     982                                               1 \[Reference\]                                                534    1 \[Reference\]     
                                                                                     45--55            3933     513                                               0.97 (0.88, 1.08)                                              279    0.89 (0.78, 1.02)   
                                                                                     Over 55           1625     218                                               0.95 (0.82, 1.09)                                              94     0.79 (0.64, 0.96)   

3TC, lamivudine; ART, antiretroviral therapy; CI, confidence interval; Dx, diagnosis; FTC, emtricitabine; IRR, incidence rate ratio; LTFU, lost to follow-up; VF, virological failure; VL, viral load.

^a^Estimated using Poisson regression models with adjustment for cohort and all variables listed in this table.

^b^Multiple imputation used for missing data.

^c^Multiple imputation not used for ethnicity in cohorts with no data on this variable: ethnicity was set to reference and these cohorts have not been included in ethnicity rows of *n* patients and *n* events in this table.

^d^*n* Patients and *n* events are given according to baseline age at start of ART.

^\*^Univariate or multivariate Wald test.
